{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:26:35Z","timestamp":1787124395828,"version":"build-2736575974"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Programmed cell death protein 1 (PD-1, CD279) is a pivotal inhibitory immune checkpoint receptor that plays a central role in maintaining immune homeostasis and peripheral tolerance. Originally characterized as a negative regulator of T-cell activation, PD-1 limits excessive immune responses and prevents autoimmunity, while its sustained expression under conditions of chronic antigen stimulation contributes to T-cell dysfunction and exhaustion. The discovery that blockade of the PD-1 pathway can restore anti-tumor immunity has revolutionized cancer therapy and established immune checkpoint inhibition as a cornerstone of modern oncology. Although PD-1 has traditionally been viewed as a key regulator of adaptive immunity, accumulating evidence indicates that its biological functions extend beyond T cells. In recent years, PD-1 expression has been identified in several innate immune cell populations, particularly Natural Killer (NK) cells, where it has emerged as an important modulator of effector functions, cytokine production, metabolic fitness, and antitumor activity. These findings have challenged the classical view of PD-1 biology and revealed unexpected similarities between NK-cell dysfunction and the exhausted phenotype described in chronically stimulated T cells. In the tumor microenvironment, PD-1 expression on NK cells has been associated with impaired cytotoxicity and reduced immune surveillance, suggesting that NK cells may also represent relevant targets of PD-1-mediated immunosuppression. At the same time, the mechanisms regulating PD-1 expression and signaling in NK cells appear to differ, at least in part, from those operating in T lymphocytes, highlighting the complexity of this pathway across distinct immune cell subsets. In this review, we summarize the current knowledge of PD-1 biology, from its established role in T-cell regulation to its emerging functions in NK cells. We discuss the molecular mechanisms governing PD-1 expression and signaling, its contribution to immune dysfunction in cancer and chronic diseases, and the potential implications of targeting the PD-1 axis to enhance both adaptive and innate antitumor immunity.<\/jats:p>","DOI":"10.3389\/fcell.2026.1924522","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:59:31Z","timestamp":1787122771000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Programmed cell death-1: from a T-cell immune checkpoint to a regulator of Natural Killer cell biology"],"prefix":"10.3389","volume":"14","author":[{"given":"Fabiana","family":"De Franco","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Greppi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Obino","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Rebaudi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Goda","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Caffa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties, University of Genoa","place":["Genoa, Italy"]},{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bozzo","sequence":"additional","affiliation":[{"name":"Department of Earth, Environmental and Life Sciences, DISTAV, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Melaiu","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata","place":["Rome, Italy"]},{"name":"Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Ges\u00f9 Children Hospital, IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Munari","sequence":"additional","affiliation":[{"name":"Pathology Unit, Verona University Hospital Trust","place":["Verona, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio Gaetano","family":"Vellone","sequence":"additional","affiliation":[{"name":"Department of Integrated Surgical and Diagnostic Sciences, University of Genoa","place":["Genoa, Italy"]},{"name":"Pathology Unit, IRCCS Istituto Giannina Gaslini","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Jandus","sequence":"additional","affiliation":[{"name":"Department of Pathology and Immunology, Faculty of Medicine, University of Geneva","place":["Geneva, Switzerland"]},{"name":"Ludwig Institute for Cancer Research, Lausanne Branch","place":["Lausanne, Switzerland"]},{"name":"Geneva Center for Inflammation Research","place":["Geneva, Switzerland"]},{"name":"Translational Research Centre in Onco-Haematology (CRTOH)","place":["Geneva, Switzerland"]},{"name":"Institute of Genetics and Genomics of Geneva (iGE3), University of Geneva","place":["Geneva, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mavilio","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Department of Medical Biotechnology and Translational Medicine, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Candiani","sequence":"additional","affiliation":[{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]},{"name":"Department of Earth, Environmental and Life Sciences, DISTAV, University of Genoa","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Pesce","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]},{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Marcenaro","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, DIMES, University of Genoa","place":["Genoa, Italy"]},{"name":"AOM - IRCCS Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/J.CELL.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/JEM.20022125","article-title":"The programmed Death-1 (PD-1) pathway regulates autoimmune diabetes in Nonobese diabetic (NOD) mice","volume":"198","author":"Ansari","year":"2003","journal-title":"J. Exp. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/J.MAYOCP.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/S41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1182\/blood-2013-03-489054","article-title":"Identification of a cellular ligand for the natural cytotoxicity receptor NKp44","volume":"122","author":"Baychelier","year":"2013","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/ONCOTARGET.12150","article-title":"PD-1 mediates functional exhaustion of activated NK cells in patients with kaposi sarcoma","volume":"7","author":"Beldi-Ferchiou","year":"2016","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/J.IMMUNI.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/BLOOD-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1158\/2159-8290.CD-15-0944","article-title":"Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy","volume":"6","author":"Blake","year":"2016","journal-title":"Cancer Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/S00262-006-0272-1","article-title":"Contribution of the PD-L1\/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion","volume":"56","author":"Blank","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/S00262-004-0593-X","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/J.CELL.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1084\/JEM.194.3.235","article-title":"NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill epstein-barr virus-infected B cells in X-linked lymphoproliferative disease","volume":"194","author":"Bottino","year":"2001","journal-title":"J. Exp. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e220007","DOI":"10.20900\/IMMUNOMETAB20220007","article-title":"Effects of PD-1 signaling on immunometabolic reprogramming","volume":"4","author":"Boussiotis","year":"2022","journal-title":"Immunometabolism"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1084\/JEM.20090681","article-title":"The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans","volume":"206","author":"Brandt","year":"2009","journal-title":"J. Exp. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/J.CELL.2017.04.004","article-title":"Metabolic instruction of immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","article-title":"PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2","volume":"32","author":"Carter","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/JIMMUNOL.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/NATURE21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/SCITRANSLMED.AAZ5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","article-title":"PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients","volume":"6","author":"Concha-Benavente","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-infiltrating natural killer cells","volume":"11","author":"C\u00f3zar","year":"2021","journal-title":"Cancer Discov."},{"key":"B25","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/J.IMMUNI.2018.09.009","article-title":"High-dimensional single-cell analysis identifies organ-specific signatures and conserved NK cell subsets in humans and mice","volume":"49","author":"Crinier","year":"2018","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"101424","DOI":"10.1016\/J.SMIM.2020.101424","article-title":"Multidimensional molecular controls defining NK\/ILC1 identity in cancers","volume":"52","author":"Crinier","year":"2021","journal-title":"Semin. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"Da Silva","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/CYTO.B.21508","article-title":"Markers and function of human NK cells in normal and pathological conditions","volume":"92","author":"Del","year":"2017","journal-title":"Cytom. B Clin. Cytom."},{"key":"B29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/CYTO.A.24001","article-title":"Comprehensive phenotyping of human PB NK cells by flow cytometry","volume":"97","author":"Del","year":"2020","journal-title":"Cytom. Part A"},{"key":"B30","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","article-title":"Tissue determinants of human NK cell development, function, and residence","volume":"180","author":"Dogra","year":"2020","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/EJI.200424886","article-title":"Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells","volume":"34","author":"Falco","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41375-024-02271-1","article-title":"PD-1 expression contributes to functional impairment of NK cells in patients with B-CLL","volume":"38","author":"Farhat","year":"2024","journal-title":"Leukemia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/JEM.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/J.CELREP.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/nejmoa1501824","article-title":"Pembrolizumab for the treatment of Non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/S11864-023-01069-0","article-title":"Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches","volume":"24","author":"Geurts","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/BLOOD-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/IJMS20040890","article-title":"Strengthening the AntiTumor NK cell function for the treatment of ovarian cancer","volume":"20","author":"Greppi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1183215","DOI":"10.3389\/fimmu.2023.1183215","article-title":"Identification of a novel cord blood NK cell subpopulation expressing functional programmed death receptor-1","volume":"14","author":"Greppi","year":"2023","journal-title":"Front. Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"106932","DOI":"10.1016\/J.IMLET.2024.106932","article-title":"NK cell receptors in anti-tumor and healthy tissue protection: mechanisms and therapeutic advances","volume":"270","author":"Greppi","year":"2024","journal-title":"Immunol. Lett."},{"key":"B41","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/S13046-025-03508-2","article-title":"PD-1+ NK cell subsets in high grade serous ovarian cancer: an indicator of disease severity and a target for combined immune-checkpoint blockade","volume":"44","author":"Greppi","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"753890","DOI":"10.3389\/fimmu.2021.753890","article-title":"Post-transplant nivolumab plus unselected autologous lymphocytes in refractory hodgkin lymphoma: a feasible and promising salvage therapy associated with expansion and maturation of NK cells","volume":"12","author":"Guolo","year":"2021","journal-title":"Front. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/PNAS.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1126\/sciadv.abj3286","article-title":"When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer","volume":"8","author":"Hasim","year":"2022","journal-title":"Sci. Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/CNCR.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"633361","DOI":"10.3389\/fimmu.2021.633361","article-title":"The adverse impact of tumor microenvironment on NK-Cell","volume":"12","author":"Hu","year":"2021","journal-title":"Front. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/J.BJ.2019.09.002","article-title":"Immune checkpoint inhibitors win the 2018 Nobel Prize","volume":"42","author":"Huang","year":"2019","journal-title":"Biomed. J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/SCIENCE.AAF1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41420-026-03063-5","article-title":"Lactate-mediated NK cell dysfunction as a prognostic marker and therapeutic target in breast cancer","volume":"12","author":"Ielpo","year":"2026","journal-title":"Cell Death Discov."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/J.1460-2075.1992.TB05481.X","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/PNAS.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e20231704","DOI":"10.1084\/JEM.20231704","article-title":"Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency","volume":"221","author":"Johnson","year":"2024","journal-title":"J. Exp. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"519676","DOI":"10.3389\/fcimb.2020.00049","article-title":"Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence","volume":"10","author":"Judge","year":"2020","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection","volume":"12","author":"Kao","year":"2011","journal-title":"Nat. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1634\/THEONCOLOGIST.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"B56","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/JEM.20051776","article-title":"Tissue expression of PD-L1 mediates peripheral T cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1084\/jem.20051776","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/J.CELL.2018.08.039","article-title":"A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging","volume":"174","author":"Keren","year":"2018","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"816658","DOI":"10.3389\/fimmu.2021.816658","article-title":"Back to the future: Spatiotemporal determinants of NK cell antitumor function","volume":"12","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"B62","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","article-title":"Expansion of a unique CD57 +NKG2C hi natural killer cell subset during acute human cytomegalovirus infection","volume":"108","author":"Lopez-Verg\u00e8s","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B63","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2326-6066.cir-13-0133","article-title":"PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection","volume":"2","author":"MacFarlane","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/J.AUTREV.2005.04.015","article-title":"NK-DC interaction: on the usefulness of auto-aggression","volume":"4","author":"Marcenaro","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1557030","DOI":"10.1080\/2162402X.2018.1557030","article-title":"PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression","volume":"8","author":"Mariotti","year":"2019","journal-title":"Oncoimmunology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41590-018-0251-7","article-title":"Metabolic reprogramming of natural killer cells in obesity limits antitumor responses","volume":"19","author":"Michelet","year":"2018","journal-title":"Nat. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/ANNUREV.IMMUNOL.19.1.197","article-title":"Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis","volume":"19","author":"Moretta","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/NRC.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer May contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e150079","DOI":"10.1172\/JCI.INSIGHT.150079","article-title":"Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion","volume":"7","author":"Myers","year":"2022","journal-title":"JCI Insight"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","article-title":"Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping","volume":"25","author":"Netskar","year":"2024","journal-title":"Nat. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1578444","DOI":"10.3389\/fimmu.2025.1578444","article-title":"Colorectal cancer-infiltrating NK cell landscape analysis unravels tissue-resident PD-1+ NK cells in microsatellite instability tumors","volume":"16","author":"Obino","year":"2025","journal-title":"Front. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/JIMMUNOL.181.7.4832","article-title":"NFATc1 regulates PD-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J. Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-021-01388-5","article-title":"Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child","volume":"27","author":"Ogishi","year":"2021","journal-title":"Nat. Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/S41577-019-0139-2","article-title":"Immunometabolism and natural killer cell responses","volume":"19","author":"O\u2019Brien","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.3390\/CANCERS13071496","article-title":"New insights into endometrial cancer","volume":"13","author":"Paleari","year":"2021","journal-title":"Cancers"},{"key":"B78","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/NRC3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"32722","DOI":"10.18632\/ONCOTARGET.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"B80","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/SCIADV.ABD2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci. Adv."},{"key":"B82","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/NCOMMS7692","article-title":"PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation","volume":"6","author":"Patsoukis","year":"2015","journal-title":"Nat. Commun."},{"key":"B83","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/J.IT.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1001224","DOI":"10.1080\/2162402X.2014.1001224","article-title":"B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape","volume":"4","author":"Pesce","year":"2015","journal-title":"Oncoimmunology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/J.JACI.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"464453","DOI":"10.3389\/fimmu.2019.01242","article-title":"PD\/1-PD-Ls checkpoint: insight on the potential role of NK cells","volume":"10","author":"Pesce","year":"2019","journal-title":"Front. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.3390\/CANCERS12123504","article-title":"Cancer immunotherapy by blocking immune checkpoints on innate lymphocytes","volume":"12","author":"Pesce","year":"2020","journal-title":"Cancers"},{"key":"B88","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/J.IMMUNI.2007.10.010","article-title":"Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells","volume":"27","author":"Pogge von Strandmann","year":"2007","journal-title":"Immunity"},{"key":"B89","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41590-018-0185-0","article-title":"Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells","volume":"19","author":"Quatrini","year":"2018","journal-title":"Nat. Immunol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/J.JACI.2020.04.044","article-title":"Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells","volume":"147","author":"Quatrini","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/BLOOD-2013-09-523696","article-title":"Found: a cellular activating ligand for NKp44","volume":"122","author":"Rajagopalan","year":"2013","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/J.CTRV.2024.102831","article-title":"The landscape of combining immune checkpoint inhibitors with novel therapies: secret alliances against breast cancer","volume":"130","author":"Rebaudi","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"B93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/S10555-025-10242-W","article-title":"The diversity of natural killer cell functional and phenotypic states in cancer","volume":"44","author":"Rishabh","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/nejmoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/S41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat. Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"15776","DOI":"10.1038\/ncomms15776","article-title":"IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours","volume":"8","author":"Seo","year":"2017","journal-title":"Nat. Commun."},{"key":"B97","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/SCIENCE.AAA8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3\u03b6 signalosome and downstream signaling to PKC\u03b8","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e1343775","DOI":"10.1080\/2162402X.2017.1343775","article-title":"PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18\/CHO","volume":"6","author":"Siebert","year":"2017","journal-title":"Oncoimmunology"},{"key":"B100","first-page":"787","article-title":"2B4 functions as a co-receptor in human NK cell activation","volume-title":"Eur. J. Immunol.","author":"Sivori","year":"2000"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/EJI.1830261032","article-title":"CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies","volume":"26","author":"Sivori","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"E00020","DOI":"10.1097\/IN9.0000000000000020","article-title":"Metabolic regulation of NK cell function: implications for immunotherapy","volume":"5","author":"Sohn","year":"2023","journal-title":"Immunometabolism (Cobham, Surrey)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2014.10.013","article-title":"The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8+ T cells during chronic infection","volume":"41","author":"Staron","year":"2014","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/S00262-022-03317-Y","article-title":"Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy","volume":"72","author":"Susek","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B105","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1016\/J.CELL.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front. Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMOA1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/S00262-020-02558-Z","article-title":"PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1\/PD-L1 blockade","volume":"69","author":"Trefny","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/IJC.32262","article-title":"Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: functional analysis and expression of PD-1 receptor","volume":"145","author":"Tumino","year":"2019","journal-title":"Int. J. Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/S41385-019-0141-9","article-title":"PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua","volume":"12","author":"Vacca","year":"2019","journal-title":"Mucosal Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"Van Hall","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/BLOOD-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/S41573-024-01098-W","article-title":"Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer","volume":"24","author":"Viel","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"B114","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"B115","doi-asserted-by":"publisher","first-page":"9018","DOI":"10.1200\/JCO.2015.33.15_SUPPL.9018","article-title":"Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled analysis","volume":"33","author":"Weber","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti\u2013CTLA-4 plus anti\u2013PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B117","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/NI.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/EJI.201141832","article-title":"Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD","volume":"42","author":"Wiesmayr","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/JEM.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J. Exp. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/J.IMMUNI.2011.06.015","article-title":"Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells","volume":"35","author":"Youngblood","year":"2011","journal-title":"Immunity"},{"key":"B121","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1924522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:59:33Z","timestamp":1787122773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1924522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":121,"alternative-id":["10.3389\/fcell.2026.1924522"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1924522","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1924522"}}